source
- Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancerA recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
- Ibrutinib monotherapy shows ten-year durable efficacy across CLL subtypesIbrutinib monotherapy has demonstrated lasting effectiveness in chronic lymphocytic leukemia across multiple disease subtypes. Data reveal that patients, including those with TP53 mutations, maint…